article thumbnail

The next phase of the multiomics evolution, powered by AI

Drug Target Review

In 2009, he won the annual Illumina Innovation Award for the development of RTA, the on-instrument real-time primary analysis software for sequencing. Francisco’s experience includes almost 19 years at Illumina, most recently as Vice President of Software Engineering and Embedded Systems.

RNA 72
article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

Liu became an HHMI investigator in 2005 and joined the JASONs, academic science advisors to the US government, in 2009. He earned his PhD in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. In 2016, he became a core institute member at the Broad Institute.

Science 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia. Sadelain and Rivire also developed safe and reliable ways to produce these cells for use in patients.

Therapies 119
article thumbnail

Assembling data sets for training ML bioactivity models

Molecular Design

Back in 2009 I discussed (see K2009 ) the difference between hypothesis-driven molecular design and prediction-driven molecular design and I suggest that the former can be accommodated within an AI design framework. This is a good point at which to wrap up and I'll share some thoughts on the use of QSAR-like ML models in drug design.

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

A Legacy of Collaborative Excellence The relationship between Bayer and Tsinghua University began in 2009 as part of a broader effort by Bayer to establish strong academic linkages in Asia’s rapidly advancing research landscape.

article thumbnail

Gepirone

New Drug Approvals

5] It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. Schatzberg AF, Nemeroff CB (2009). The FDA rejected approval for gepirone in 2002 and 2004. [5] National Institute of Child Health and Human Development. PMID 37856644.

FDA 62
article thumbnail

Elacestrant 

New Drug Approvals

2] [4] Pharmacology Pharmacodynamics Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , specifically targeting the estrogen receptor alpha (ER), which is the biological target of endogenous estrogens like estradiol. [1] 1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1]

FDA 62